This finding challenges the limitations of traditional immunosuppressive theories of sepsis and provides an innovative theoretical foundation for targeting CD4+ T cells or the Bcl-2 pathway in the treatment of sepsis (Stromberg et al., 2009). This evidence concerns the gene CD4 and Sepsis.